Molecular Templates, Inc. (MTEM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 35.38 Million USD | -63.73% |
| 2022 | 97.54 Million USD | -49.29% |
| 2021 | 192.36 Million USD | 37.52% |
| 2020 | 139.87 Million USD | -19.7% |
| 2019 | 174.2 Million USD | 24.29% |
| 2018 | 140.15 Million USD | 55.06% |
| 2017 | 90.39 Million USD | 272.24% |
| 2016 | 24.28 Million USD | -54.75% |
| 2015 | 53.66 Million USD | -21.53% |
| 2014 | 68.39 Million USD | -34.31% |
| 2013 | 104.11 Million USD | 16.31% |
| 2012 | 89.52 Million USD | 299.01% |
| 2011 | 22.43 Million USD | 38.46% |
| 2010 | 16.2 Million USD | -66.72% |
| 2009 | 48.68 Million USD | 98.46% |
| 2008 | 24.53 Million USD | -4.97% |
| 2007 | 25.81 Million USD | -54.74% |
| 2006 | 57.03 Million USD | -44.14% |
| 2005 | 102.1 Million USD | 216.96% |
| 2004 | 32.21 Million USD | -21.95% |
| 2003 | 41.27 Million USD | 513.59% |
| 2002 | 6.72 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 26.69 Million USD | -1.56% |
| 2024 Q1 | 27.11 Million USD | -23.36% |
| 2023 Q3 | 44.06 Million USD | 24.07% |
| 2023 Q4 | 35.38 Million USD | -19.7% |
| 2023 FY | 35.38 Million USD | -63.73% |
| 2023 Q2 | 35.51 Million USD | -54.76% |
| 2023 Q1 | 78.5 Million USD | -19.52% |
| 2022 Q1 | 163.16 Million USD | -15.18% |
| 2022 Q4 | 97.54 Million USD | -17.78% |
| 2022 Q2 | 140.8 Million USD | -13.7% |
| 2022 FY | 97.54 Million USD | -49.29% |
| 2022 Q3 | 118.64 Million USD | -15.74% |
| 2021 Q1 | 251.77 Million USD | 80.0% |
| 2021 FY | 192.36 Million USD | 37.52% |
| 2021 Q3 | 217.92 Million USD | -10.96% |
| 2021 Q4 | 192.36 Million USD | -11.73% |
| 2021 Q2 | 244.76 Million USD | -2.79% |
| 2020 Q3 | 169.37 Million USD | 18.94% |
| 2020 Q4 | 139.87 Million USD | -17.42% |
| 2020 FY | 139.87 Million USD | -19.7% |
| 2020 Q2 | 142.41 Million USD | -11.41% |
| 2020 Q1 | 160.74 Million USD | -7.73% |
| 2019 Q2 | 131.14 Million USD | -6.73% |
| 2019 Q1 | 140.6 Million USD | 0.32% |
| 2019 Q3 | 93.16 Million USD | -28.96% |
| 2019 FY | 174.2 Million USD | 24.29% |
| 2019 Q4 | 174.2 Million USD | 86.99% |
| 2018 Q2 | 79.41 Million USD | -8.94% |
| 2018 Q4 | 140.15 Million USD | -7.77% |
| 2018 FY | 140.15 Million USD | 55.06% |
| 2018 Q1 | 87.21 Million USD | -3.51% |
| 2018 Q3 | 151.96 Million USD | 91.35% |
| 2017 Q4 | 90.39 Million USD | -11.85% |
| 2017 FY | 90.39 Million USD | 272.24% |
| 2017 Q3 | 102.53 Million USD | 391.52% |
| 2017 Q2 | 20.86 Million USD | 4.55% |
| 2017 Q1 | 19.95 Million USD | -17.83% |
| 2016 Q2 | 36.18 Million USD | -11.86% |
| 2016 Q1 | 41.05 Million USD | -23.51% |
| 2016 Q4 | 24.28 Million USD | -18.21% |
| 2016 FY | 24.28 Million USD | -54.75% |
| 2016 Q3 | 29.69 Million USD | -17.94% |
| 2015 FY | 53.66 Million USD | -21.53% |
| 2015 Q4 | 53.66 Million USD | -16.09% |
| 2015 Q3 | 63.96 Million USD | -13.39% |
| 2015 Q2 | 73.85 Million USD | -16.08% |
| 2015 Q1 | 88 Million USD | 28.68% |
| 2014 Q1 | 94.68 Million USD | -9.06% |
| 2014 FY | 68.39 Million USD | -34.31% |
| 2014 Q3 | 76.67 Million USD | -8.91% |
| 2014 Q2 | 84.17 Million USD | -11.1% |
| 2014 Q4 | 68.39 Million USD | -10.79% |
| 2013 Q1 | 113.87 Million USD | 27.2% |
| 2013 Q4 | 104.11 Million USD | 3.04% |
| 2013 Q3 | 101.04 Million USD | -3.31% |
| 2013 Q2 | 104.5 Million USD | -8.23% |
| 2013 FY | 104.11 Million USD | 16.31% |
| 2012 Q4 | 89.52 Million USD | 3.83% |
| 2012 FY | 89.52 Million USD | 299.01% |
| 2012 Q3 | 86.21 Million USD | -0.14% |
| 2012 Q2 | 86.34 Million USD | -3.76% |
| 2012 Q1 | 89.71 Million USD | 299.87% |
| 2011 Q3 | 26.87 Million USD | -18.54% |
| 2011 Q4 | 22.43 Million USD | -16.52% |
| 2011 Q1 | 39.79 Million USD | 145.61% |
| 2011 FY | 22.43 Million USD | 38.46% |
| 2011 Q2 | 32.99 Million USD | -17.1% |
| 2010 Q2 | 28.18 Million USD | -35.09% |
| 2010 Q4 | 16.2 Million USD | -26.08% |
| 2010 FY | 16.2 Million USD | -66.72% |
| 2010 Q1 | 43.41 Million USD | -10.82% |
| 2010 Q3 | 21.92 Million USD | -22.22% |
| 2009 Q3 | 20.88 Million USD | 44.26% |
| 2009 Q1 | 19.11 Million USD | -22.07% |
| 2009 Q2 | 14.47 Million USD | -24.29% |
| 2009 FY | 48.68 Million USD | 98.46% |
| 2009 Q4 | 48.68 Million USD | 133.17% |
| 2008 Q2 | 16.64 Million USD | -20.32% |
| 2008 Q4 | 24.53 Million USD | -15.36% |
| 2008 Q3 | 28.98 Million USD | 74.12% |
| 2008 Q1 | 20.89 Million USD | -19.07% |
| 2008 FY | 24.53 Million USD | -4.97% |
| 2007 Q2 | 38.91 Million USD | -16.57% |
| 2007 FY | 25.81 Million USD | -54.74% |
| 2007 Q1 | 46.64 Million USD | -18.22% |
| 2007 Q3 | 33 Million USD | -15.19% |
| 2007 Q4 | 25.81 Million USD | -21.79% |
| 2006 Q4 | 57.03 Million USD | -16.3% |
| 2006 Q2 | 81.2 Million USD | -11.19% |
| 2006 FY | 57.03 Million USD | -44.14% |
| 2006 Q3 | 68.13 Million USD | -16.09% |
| 2006 Q1 | 91.43 Million USD | -10.44% |
| 2005 Q4 | 102.1 Million USD | 106.28% |
| 2005 Q1 | 64.06 Million USD | 98.89% |
| 2005 Q3 | 49.49 Million USD | -14.59% |
| 2005 Q2 | 57.95 Million USD | -9.55% |
| 2005 FY | 102.1 Million USD | 216.96% |
| 2004 FY | 32.21 Million USD | -21.95% |
| 2004 Q3 | 31.37 Million USD | 0.0% |
| 2004 Q4 | 32.21 Million USD | 2.67% |
| 2003 FY | 41.27 Million USD | 513.59% |
| 2002 FY | 6.72 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -11728.676% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -516.858% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -140.783% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -13.353% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -998.851% |
| Better Therapeutics, Inc. | 22.94 Million USD | -54.221% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -23.389% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -849.341% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -72.23% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -67.509% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 45.092% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -1403.286% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 50.163% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -35.354% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -46460.867% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -190.763% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -709.382% |
| NexImmune, Inc. | 8.59 Million USD | -311.72% |
| Orgenesis Inc. | 14.55 Million USD | -143.149% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -199.805% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -28287.475% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -522.896% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -8920.178% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 92.517% |
| Statera Biopharma, Inc. | 21.16 Million USD | -67.14% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -250.153% |
| Trevena, Inc. | 40.6 Million USD | 12.86% |
| Vaxxinity, Inc. | 44.35 Million USD | 20.224% |
| Vaccinex, Inc. | 3.63 Million USD | -874.47% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -89124.834% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 37.587% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -6267.113% |